Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Pulmonary rehabilitation in Iranian outpatients with mustard gas lung disease: a randomised controlled trial [with consumer summary]
Ghanei M, Philip KEJ, Moghadam MRS, Hosseini H, Babaie A, Roustanezhad M, Hopkinson NS
BMJ Open 2024 May;14(5):e083085
clinical trial
This trial has not yet been rated.

OBJECTIVE: People with mustard gas lung disease experience cough, sputum, breathlessness and exercise limitation. We hypothesised that pulmonary rehabilitation (PR) would be beneficial in this condition. DESIGN: An assessor-blind, two-armed, parallel-design randomised controlled clinical trial. SETTING: Secondary care clinics in Iran. PARTICIPANTS: 60 men with breathlessness due to respiratory disease caused by documented mustard gas exposure, mean (SD) age 52.7 (4.36) years, MRC dyspnoea score 3.5 (0.7), St. George's Respiratory Questionnaire (SGRQ) 72.3 (15.2). INTERVENTIONS: Participants were allocated either to a 6-week course of thrice-weekly PR (n = 31) or to usual care (n = 29), with 6-week data for 28 and 26, respectively. OUTCOME MEASURES: Primary endpoint was change in cycle endurance time at 70% baseline exercise capacity at 6 weeks. Secondary endpoints included 6 min walk distance, quadriceps strength and bulk, body composition and health status. For logistical reasons, blood tests that had been originally planned were not performed and 12-month follow-up was available for only a small proportion. RESULTS: At 6 weeks, cycle endurance time increased from 377 (140) s to 787 (343) s with PR versus 495 (171) s to 479 (159) s for usual care, effect size plus 383 (231) s (p < 0.001). PR also improved 6 min walk distance plus 103.2 m (63.6 to 142.9) (p < 0.001), MRC dyspnoea score -0.36 (-0.65 to -0.07) (p = 0.016) and quality of life; SGRQ -8.43 (-13.38 to -3.48) p < 0.001, as well as quadriceps strength plus 9.28 Nm (1.89 to 16.66) p = 0.015. CONCLUSION: These data suggest that PR can improve exercise capacity and quality of life in people with breathlessness due to mustard gas lung disease and support the wider provision of this form of care. TRIAL REGISTRATION NUMBER: IRCT2016051127848N1.
Reproduced with permission from the BMJ Publishing Group.

Full text (sometimes free) may be available at these link(s):      help